DelveInsight’s “ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Insight, 2026” report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in the ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers ALK+ NSCLC pipeline drug profiles, including clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type, and highlights inactive pipeline products in this space.
To know in detail about the ALK+ NSCLC pipeline landscape, emerging drug profiles, clinical trial status, and development activities, Click here: ALK+ NSCLC Pipeline Insight Report
Some of the Key Facts of the ALK+ NSCLC Pipeline Report:
- DelveInsight’s ALK+ NSCLC Pipeline Report covers 6+ key companies and 7+ pipeline products across various stages of clinical development, including Phase III, Phase II, Phase I, preclinical, and discovery.
- About 90% of patients diagnosed with ALK-positive cancer are diagnosed at the metastatic (stage 4) stage. Without treatment, median survival was less than 12 months; with modern therapies, that figure has increased more than six-fold to over six years in the last decade.
- Shouyao Holdings is advancing Ficonalkib (SY-3505), a highly potent, CNS-penetrant, 3rd-generation ALK TKI, currently under Phase III clinical evaluation for NSCLC treatment. It demonstrates potent inhibition against wild-type ALK and a diverse spectrum of resistance mutants, including L1196M, G1202R, F1174L, G1269S, and R1275Q.
- Ascentage Pharma is developing APG-2449, an orally available, small-molecule FAK/ALK/ROS1 TKI and the first China-developed third-generation ALK inhibitor entering clinical development, currently in Phase I clinical trials for NSCLC. Updated results at ASCO demonstrated favorable safety and promising antitumor activity, with encouraging preliminary efficacy in patients resistant to second-generation ALK inhibitors.
- In August 2020, ensartinib demonstrated longer progression-free survival compared with crizotinib (Xalkori) in patients with ALK-positive NSCLC, according to clinical trial data presented at the IASLC World Conference on Lung Cancer Virtual Presidential Symposium.
- ALK gene rearrangements lead to constitutive activation of the ALK kinase and subsequent ALK-driven tumor formation. Patients harboring such rearrangements are highly sensitive to ALK inhibitors such as crizotinib, ceritinib, and alectinib.
- The NCCN recommends broad, panel-based molecular testing — typically by next-generation sequencing (NGS) — for all patients with advanced-stage adenocarcinoma, regardless of gender, smoking history, other risk factors, or race. For patients without identifiable driver oncogenes by DNA NGS, RNA-based NGS is recommended to maximize detection of fusion events.
- The ALK+ NSCLC pipeline features drug candidates spanning small molecules, peptides, and oligonucleotides, with routes of administration including oral, intravenous, subcutaneous, parenteral, and others.
- Key ALK+ NSCLC Pipeline Companies: Shouyao Holdings, Ascentage Pharma, and others developing targeted therapies across mid- to early-stage clinical development.
- Key ALK+ NSCLC Pipeline Therapies: Ficonalkib (SY-3505), APG-2449, and others in Phase III, Phase II, Phase I, and preclinical stages.
- The ALK+ NSCLC pipeline is expected to witness significant advancement driven by novel CNS-penetrant TKIs, next-generation ALK inhibitors addressing resistance mutations, and combination approaches targeting multiple resistance mechanisms.
ALK+ NSCLC Overview
ALK-positive Non-Small Cell Lung Cancer is driven by rearrangements of the anaplastic lymphoma kinase (ALK) gene, most commonly involving fusion with the echinoderm microtubule-associated protein-like 4 (EML4) gene. These rearrangements lead to constitutive activation of the ALK kinase and subsequent tumor formation. Lung cancer often shows no symptoms until it has spread, with common signs including cough, chest pain, hoarseness, coughing up blood, and fatigue.
Diagnosis involves genetic/molecular testing of a tissue sample, typically obtained via needle biopsy. Consensus guidelines recommend all patients with advanced-stage adenocarcinoma be tested for ALK and EGFR mutations via a broad, panel-based approach using NGS.
Get a Free Sample for the ALK+ NSCLC Pipeline Report
ALK+ NSCLC Pipeline Therapeutics Assessment
The therapeutics assessment section provides insights into the pipeline drugs segmented across multiple parameters covering the full scope of the report:
ALK+ NSCLC Pipeline Segmentation:
The ALK+ NSCLC Pipeline Report proffers assessment of pipeline candidates segmented by:
- Stage of Development: Phase III, Phase II, Phase I/II, Phase I, Preclinical, and Discovery
- Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical, Transdermal, Intrathecal, Intraocular, Intra-articular
- Molecule Type: Small molecule, Peptide, Oligonucleotide
- Product Type: Mono, Combination, and Mono/Combination
Download the report to understand the full ALK+ NSCLC pipeline landscape and development activity @ ALK+ NSCLC Pipeline Assessment
ALK+ NSCLC Emerging Drugs and Pipeline Development Activities
The emerging drugs section provides a detailed analysis of various drugs in different stages of clinical development, including Phase II, Phase I, preclinical, and discovery. It covers ALK+ NSCLC clinical trial details, pharmacological action, agreements and collaborations, and the latest news and press releases.
The report also covers ALK+ NSCLC Pipeline Development Activities — providing detailed information on collaborations, acquisitions and mergers, licensing arrangements, and a thorough therapeutic assessment of all ALK+ NSCLC emerging drugs.
ALK+ NSCLC Emerging Drug Profiles and Key Companies
- Ficonalkib (SY-3505): Shouyao Holdings — Phase III; 3rd-generation CNS-penetrant ALK TKI active against wild-type and resistance mutants
- APG-2449: Ascentage Pharma — Phase I; oral FAK/ALK/ROS1 TKI; first China-developed 3rd-gen ALK inhibitor in clinical development
Discover more about the therapies set to shape the ALK+ NSCLC treatment landscape @ ALK+ NSCLC Emerging Therapies
ALK+ NSCLC Pipeline Drivers
- Robust and expanding pipeline of next-generation ALK TKIs addressing resistance to 1st- and 2nd-generation inhibitors
- Increasing adoption of broad NGS-based molecular testing driving earlier identification of ALK+ patients
- Growing focus on CNS-penetrant inhibitors to address brain metastases, a common complication in ALK+ NSCLC
- Strong clinical data supporting improved survival outcomes with modern ALK-targeted therapies
- Active collaboration and licensing activity among pharmaceutical companies and academic institutions advancing novel candidates
ALK+ NSCLC Pipeline Barriers
- Development of acquired resistance mutations limiting the durability of existing ALK inhibitor therapies
- High rate of metastatic disease at diagnosis complicating treatment sequencing
- Limited availability of molecular testing infrastructure in certain geographies, leading to underdiagnosis of ALK-positive cases
Scope of the ALK+ NSCLC Pipeline Report
- Coverage: Global
- Key ALK+ NSCLC Companies: Shouyao Holdings, Ascentage Pharma, and 4+ additional companies developing ALK+ NSCLC candidates
- Key ALK+ NSCLC Pipeline Therapies: Ficonalkib (SY-3505), APG-2449, and 5+ additional pipeline products across stages
- Pipeline Therapeutics Assessment: Stage-wise, ROA-wise, molecule-type-wise, and product-type-wise analysis
- Pipeline Development Activities: Collaborations, mergers and acquisitions, licensing, designations, and patent details
- Inactive and Discontinued Candidates: Assessment of inactive ALK+ NSCLC drugs and development history
- ALK+ NSCLC Unmet Needs, KOL Views, Clinical Trial Analysis, and Impact Assessment
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit market analysis to accelerate business growth and overcome challenges with a practical approach.
